Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,074.95 +794.61 (+1.22%) CMC Crypto 200
1,403.87 -14.00 (-0.99%)
BNGO Nov 2024 1.500 call
| Previous close | 0.1400 |
| Open | 0.1400 |
| Bid | 0.0000 |
| Ask | 0.1500 |
| Strike | 1.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.1400 - 0.1400 |
| Contract range | N/A |
| Volume | |
| Open interest | 351 |
GlobeNewswireBionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow
A record 31 scientific presentations and posters at the 2024 European Society for Human Genetics (ESHG) Annual Conference and 8 scientific presentations and posters at the 2024 American Cytogenomics Conference (ACC) will highlight the application of optical genome mapping (OGM) in genetic disorder, rare disease, and cancer research applicationsBionano will host a sponsored session at ESHG featuring an overview of the Company’s OGM workflow delivered by Bionano’s chief medical officer, Dr. Alka C
- GlobeNewswire
Bionano Announces Private Placement of Senior Secured Notes in Debt Restructuring that Improves Balance Sheet
Provides significant financial flexibility by retiring near-term debt maturities, deferring principal redemption payments, and further reducing near-term cash needsSAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics Inc. (“Bionano” or the “Company”) (NASDAQ: BNGO) today announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026. The Company received gross proceeds of $18.0 million in connection with the placement, which will allow the C
- GlobeNewswire
Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy
Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development that allows researchers in academic medical centers and biopharmaceutical companies to assess genome integrity in therapeutic cell lines like chimeric antigen receptor-modified T cells (CAR-T), stem cells, and cell lines used for translational research in unraveling genetic causes of Alzheimer’s diseaseTaken together, the publications illu
